| Literature DB >> 25369426 |
Kazushiro Takata1, Hiroki Kato2, Eku Shimosegawa2, Tatsusada Okuno1, Toru Koda1, Tomoyuki Sugimoto3, Hideki Mochizuki1, Jun Hatazawa4, Yuji Nakatsuji1.
Abstract
BACKGROUND: Activation of glial cells is a cardinal feature in multiple sclerosis (MS) pathology, and acetate has been reported to be selectively uptaken by astrocytes in the CNS. The aim of this study was to investigate the efficacy of PET with (11)C-acetate for MS diagnosis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25369426 PMCID: PMC4219725 DOI: 10.1371/journal.pone.0111598
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Patient data and demographics.
| sex | age | type | therapy | EDSS score | Disease duration (y) | GM SUVt | WM SUVt | WM/GM ratio | |
| MS 1 | F | 47 | RR | IFNβ, MTX | 7 | 10.3 | 1.0494 | 0.9415 | 0.8972 |
| MS 2 | F | 45 | RR | IFNβ | 2 | 6.8 | 1.1069 | 1.0529 | 0.9512 |
| MS 3 | F | 48 | RR | IFNβ | 1 | 5.7 | 1.0282 | 0.8874 | 0.8631 |
| MS 4 | F | 53 | RR | IFNβ | 2.5 | 7.4 | 1.0837 | 0.9434 | 0.8705 |
| MS 5 | F | 34 | RR | - | 4 | 3.3 | 0.9633 | 0.8244 | 0.8558 |
| MS 6 | F | 49 | RR | - | 1 | 1.4 | 1.0336 | 0.9044 | 0.8750 |
| HV 1 | F | 54 | 0.9149 | 0.7320 | 0.8001 | ||||
| HV 2 | F | 61 | 0.9671 | 0.8121 | 0.8397 | ||||
| HV 3 | F | 41 | 0.9518 | 0.7789 | 0.8183 | ||||
| HV 4 | F | 67 | 0.9341 | 0.7946 | 0.8507 | ||||
| HV 5 | F | 62 | 0.9449 | 0.8021 | 0.8489 | ||||
| HV 6 | F | 63 | 0.9758 | 0.8096 | 0.8297 |
MS = multiple sclerosis, HV = healthy volunteer, RR = relapsing-remitting multiple sclerosis, IFNβ = interferon beta treatment, MTX = Mitoxantrone, EDSS = Expanded Disability Status Scale, SUV = standardized uptake value.
Figure 111C-acetate CNS biodistribution.
(A)Mean standardized uptake value (SUV) of each lesion. (B) Relative SUV compared to that of the thalamus (SUVt). Data are expressed as the mean ± standard error of the mean (SEM) (n = 6). The Mann–Whitney U test showed a significant difference in the median between the HV and MS groups (*:p<0.0055 after Bonferroni correction). HV = healthy volunteers, MS = multiple sclerosis.
Figure 211C-acetate uptake distribution and quantification in MS patients.
(A)Spatially normalized group mean images of 11C-acetate SUVt automatically segmented based on MRI. VOI analysis summarizing the mean SUVt in WM (B) and GM (C), and the WM/GM SUV ratio (D) in the HV and MS groups. The identical analysis performed using spill-in-free VOIs are also shown (E–G). The p-value was calculated using the analysis of covariance to adjust the variance of age. (H) The SPM analysis result is overlaid onto the T1-weighted brain MRI template. Colored voxels indicate T-scores representing significantly increased 11C-acetate uptake (SUVt) in patients with MS compared to HV patients. The spatially normalized PET images were smoothed for the analysis using a 12-mm FWHM isotropic Gaussian kernel. The significance thresholds are corrected for multiple comparisons at the cluster level with a p-value of 0.05 (family-wise error correction). SUV: standardized uptake value.
Figure 3Correlation between 11C-acetate SUV and the number of MRI lesions in patients with MS.
Correlation between 11C-acetate SUV in WM or GM and the number of T1 black holes (A, C) or T2 lesions (B, D) in each hemisphere of the six MS patients. SUV: standardized uptake value.